Core Viewpoint - The article highlights the emergence of recombinant collagen as a significant anti-aging ingredient developed in China, marking a shift in the beauty industry where domestic brands gain authority in core raw materials, moving from a follower to a leader position in the global market [3][4][5]. Group 1: Company Overview - Marubi Biotech is one of the few companies in China that has achieved full-chain self-research and production of recombinant collagen, positioning itself as a representative of high-end beauty technology in the country [5][6]. - The company has played a crucial role in establishing national industry standards for recombinant collagen, transitioning from an industry participant to a standard setter, which signifies its technical authority [6][7]. Group 2: Technological Advancements - Marubi has developed a comprehensive research and production chain in the functional protein field, including gene editing, fermentation expression, structural verification, separation purification, and formula application [7][11]. - The establishment of the "National Recombinant Functional Protein Technology Research Center" under Marubi indicates its capability to not only serve its product development but also provide technical output to the industry [11][12]. Group 3: Product Development and Efficacy - Marubi's products, such as the "Recombinant Double Collagen," have achieved significant breakthroughs, including the first global production of high-activity recombinant human collagen through self-research and the use of translation pause technology [13][14]. - Clinical trials have shown that Marubi's products can effectively reduce wrinkle volume, with a reported 56.83% reduction in under-eye wrinkles and 13.18% in nasolabial folds after seven days of use [17][20]. Group 4: Market Strategy and Future Outlook - Marubi aims to establish a global presence by setting up research centers abroad and forming joint ventures, reflecting a shift from merely exporting products to a more comprehensive output of technology, standards, and brand culture [28][29]. - The company's vision includes creating a beauty standard that transcends cultural boundaries, emphasizing the importance of scientific research and long-term commitment to quality over short-term gains [28][30].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing short-term performance pressure due to adjustments, but the expansion of new products is expected to drive growth [1] - The company reported a revenue of 2.45 billion yuan for the first three quarters of 2025, a year-on-year increase of 25.5%, and a net profit attributable to shareholders of 240 million yuan, up 2.1% year-on-year [7] - The gross margin remains high, but the increase in sales expenses has pressured the net profit margin [7] - The company is focusing on a big product strategy to enhance user loyalty, with strong performance from flagship products [7] - The company has adjusted its profit forecasts for 2025-2027, with net profit estimates revised down to 380 million, 500 million, and 620 million yuan respectively, reflecting a year-on-year growth of 10%, 32%, and 23% [7] Financial Summary - Total revenue forecast for 2023A is 2.226 billion yuan, with a projected growth of 28.52% [1] - The net profit attributable to shareholders for 2023A is forecasted at 259.42 million yuan, with a year-on-year increase of 48.93% [1] - The latest diluted EPS for 2023A is estimated at 0.65 yuan per share [1] - The company’s P/E ratio is projected to decrease from 53.38 in 2023A to 22.51 in 2027E [1] - The gross margin for 2025 is expected to be 74.9%, with a slight increase in subsequent years [8]